ScholarIQanswers from OpenAlex & ORCID
Vassiliki Karantza
ResearcherPublications, citations & collaboration network
Vassiliki Karantza is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Vassiliki Karantza have?
ScholarIQindexed works
Vassiliki Karantza has 174 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Vassiliki Karantza have?
ScholarIQcitation count
Vassiliki Karantza has 32,011 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Vassiliki Karantza?
ScholarIQh-index
Vassiliki Karantza has an h-index of 52 in OpenAlex.
What is the i10-index of Vassiliki Karantza?
ScholarIQi10-index
Vassiliki Karantza has an i10-index of 91 in OpenAlex.
What is the ORCID of Vassiliki Karantza?
ScholarIQorcid
The ORCID for Vassiliki Karantza is on the source record.
What is the OpenAlex record for Vassiliki Karantza?
ScholarIQopenalex
The OpenAlex for Vassiliki Karantza is on the source record.
What are the most-cited papers on Vassiliki Karantza?
ScholarIQmost cited works
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Theodoros Foukakis, Peter A. Fasching, Fátima Cardoso, Michael Untch, Liyi Jia, Vassiliki Karantza, Jing Zhao, Gursel Aktan, Rebecca Dent, Joyce O’Shaughnessy
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer
Andrew Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña, Susan M. Domchek, Karen A. Gelmon, Simon J. Hollingsworth, Larissa A. Korde, Barbro Linderholm, Hanna Bandos, Elżbieta Senkus, Jennifer M. Suga, Zhimin Shao, Andrew W. Pippas, Zbigniew Nowecki, Tomasz Huzarski, Patricia A. Ganz, Peter C. Lucas, Nigel Baker, Sibylle Loibl, Robin McConnell, Martine Piccart, Rita K. Schmutzler, Guenther G. Steger, Joseph P. Costantino, Amal Arahmani, Norman Wolmark, Eleanor McFadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Nicholas C. Turner, Stefania Zambelli, Nadia Harbeck, Fabrice André, Rebecca Dent, Xuan Zhou, Vassiliki Karantza, Jaime Mejia, Javier Cortés
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Hervé Bonnefoi, Guy Jérusalem, Rupert Bartsch, Manuela Rabaglio, Roswitha Kammler, Rudolf Maibach, Mark J. Smyth, Angelo Di Leo, Marco Colleoni, Giuseppe Viale, Meredith M. Regan, Fabrice André, Debora Fumagalli, Richard D. Gelber, Theodora Goulioti, Anita Hiltbrunner, Rita L. Hui, Heidi Roschitzki, Barbara Ruepp, Frances M. Boyle, Rolf A. Stahel, Stefan Aebi, Alan S. Coates, Aron Goldhirsch, Per Karlsson, Ingrid Kössler, Stamatina Fournarakou, Adriana Gasca, Rita Pfister, Sabrina Ribeli-Hofmann, Magdelena Weber, Daniela Celotto, Carmen Comune, M. Frapolli, Magdalena Sánchez-Hohl, Hui Huang, Caitlin Mahoney, Karen N. Price, Karolyn Scott, Holly Shaw, Susan M. Fischer, Mónica Greco, Colleen King, Stefania Andrighetto, Martine Piccart, Heather E. Findlay, Michelle Jenkins, Vassiliki Karantza, Jaime Mejia, Patrick Schneier